Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study

被引:24
|
作者
Shah, A. [1 ]
Prieto-Alhambra, D. [1 ,2 ]
Hawley, S. [1 ]
Delmestri, A. [1 ]
Lippett, J. [3 ]
Cooper, C. [1 ,2 ]
Judge, A. [1 ,2 ]
Javaid, M. K. [1 ,2 ]
机构
[1] Univ Oxford, NIHR Musculoskeletal Biomed Res Unit, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Nuffield Orthopaed Ctr, Windmill Rd, Oxford OX3 7LD, England
[2] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[3] Royal Berkshire NHS Fdn Trust, Reading, Berks, England
基金
美国国家卫生研究院;
关键词
Epidemiology; Geographic variation; Hip fracture; Osteoporosis; Primary care data; Secondary fracture prevention; POSTMENOPAUSAL OSTEOPOROSIS; COST-EFFECTIVENESS; OLDER WOMEN; PERSISTENCE; ADHERENCE; RISK; INTERVENTION; DENOSUMAB; DRUGS; TRIAL;
D O I
10.1007/s00198-016-3811-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fragility fractures of the hip have a major impact on the lives of patients and their families. This study highlights significant geographical variation in secondary fracture prevention with even the highest performing regions failing the majority of patients despite robust evidence supporting the benefits of diagnosis and treatment. The purpose of the study is to describe the geographic variation in anti-osteoporosis drug therapy prescriptions before and after a hip fracture during 1999-2013 in the UK. We used primary care data (Clinical Practice Research Datalink) to identify patients with a hip fracture and primary care prescriptions of any anti-osteoporosis drugs prior to the index hip fracture and up to 5 years after. Geographic variations in prescribing before and after availability of generic oral bisphosphonates were analysed. Multivariable logistic regression models were adjusted for gender, age and body mass index (BMI). Thirteen thousand sixty-nine patients (76 % female) diagnosed with a hip fracture during 1999-2013 were identified. Eleven per cent had any anti-osteoporosis drug prescription in the 6 months prior to the index hip fracture. In the 0-4 months following a hip fracture, 5 % of patients were prescribed anti-osteoporosis drugs in 1999, increasing to 51 % in 2011 and then decreasing to 39 % in 2013. The independent predictors (OR (95 % CI)) of treatment initiation included gender (male 0.42 (0.36-0.49)), BMI (0.98 per kg/m(2) increase (0.97-1.00)) and geographic region (1.29 (0.89-1.87) North East vs. 0.56 (0.43-0.73) South Central region). Geographic differences in prescribing persisted over the 5-year follow-up. If all patients were treated at the rate of the highest performing region, then nationally, an additional 3214 hip fracture patients would be initiated on therapy every year. Significant geographic differences exist in prescribing of anti-osteoporosis drugs after hip fracture despite adjustment for potential confounders. Further work examining differences in health care provision may inform strategies to improve secondary fracture prevention after hip fracture.
引用
收藏
页码:169 / 178
页数:10
相关论文
共 50 条
  • [31] Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study
    Martinez-Laguna, Daniel
    Carbonell Abella, Cristina
    Bastida, Jose-Carlos
    Gonzalez, Milagros
    Mico-Perez, Rafael M.
    Vargas, Francisco
    Diaz Torres, Eva
    Canals, Laura
    ARCHIVES OF OSTEOPOROSIS, 2024, 19 (01)
  • [32] Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study
    Ganda, K.
    Schaffer, A.
    Seibel, M. J.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) : 543 - 551
  • [33] Hip fractures in Norway 1999-2008: time trends in total incidence and second hip fracture rates. A NOREPOS study
    Omsland, Tone K.
    Holvik, Kristin
    Meyer, Haakon E.
    Center, Jacqueline R.
    Emaus, Nina
    Tell, Grethe S.
    Schei, Berit
    Tverdal, Aage
    Gjesdal, Clara G.
    Grimnes, Guri
    Forsmo, Siri
    Eisman, John A.
    Sogaard, Anne Johanne
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2012, 27 (10) : 807 - 814
  • [34] Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture
    Michaëlsson, K
    Baron, JA
    Johnell, O
    Persson, I
    Ljunghall, S
    OSTEOPOROSIS INTERNATIONAL, 1998, 8 (06) : 540 - 546
  • [35] Incidence and seasonal variation in hip fracture incidence among elderly women in Norway. The HUNT Study
    Gronskag, Anna Brenne
    Forsmo, Siri
    Romundstad, Pal
    Langhammer, Arnulf
    Schei, Berit
    BONE, 2010, 46 (05) : 1294 - 1298
  • [36] Effect of Variation in Early Rehabilitation on Hospital Readmission After Hip Fracture
    Kumar, Amit
    Roy, Indrakshi
    Falvey, Jason
    Rudolph, James L.
    Rivera-Hernandez, Maricruz
    Shaibi, Stefany
    Sood, Pallavi
    Childers, Christine
    Karmarkar, Amol
    PHYSICAL THERAPY, 2023, 103 (03):
  • [37] Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture—limitations and scope for fracture liaison services in prevention of hip fracture
    A. Frederiksen
    B. Abrahamsen
    P. B. Johansen
    H. A. Sørensen
    Osteoporosis International, 2018, 29 : 109 - 114
  • [38] Improving Secondary Fracture Prevention After Vertebroplasty: Implementation of a Fracture Liaison Service
    Sorensen, Anna
    Gimarc, David
    Bice, Miranda
    Hare, Kristyn
    Anderson, Paul A.
    Ross, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2021, 18 (09) : 1235 - 1238
  • [39] Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study
    Fu, Shau-Huai
    Wang, Chen-Yu
    Hung, Chih-Chien
    Lee, Chia-Che
    Yang, Rong-Sen
    Huang, Chuan-Ching
    Farn, Chui-Jia
    Lin, Wei-Hsin
    Chen, Ho-Min
    Hsiao, Fei-Yuan
    Lin, Jou-Wei
    Li, Chung-Yi
    JOURNAL OF INTERNAL MEDICINE, 2021, 290 (06) : 1194 - 1205
  • [40] Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
    D. Prieto-Alhambra
    A. Judge
    N. K. Arden
    C. Cooper
    K. W. Lyles
    M. K. Javaid
    Osteoporosis International, 2014, 25 : 77 - 83